Visão geral da empresa
Check-Cap Ltd. operates as a clinical stage medical diagnostics company that specializes in developing and commercializing capsule-based screening technology products designed for the healthcare sector. The enterprise functions within the broader Healthcare industry, specifically focusing on the Diagnostics & Research sub-sector, which implies a reliance on significant research and development expenditures to advance medical technologies before achieving widespread commercial adoption. The company's current market capitalization stands at $12.03M, reflecting a small-cap status, while its incorporated history dates back to 2004 with its headquarters located in Isfiya, Israel. Although specific annual revenue and employee count figures are not disclosed in the available data, the market capitalization of $12.03M indicates that the company remains in a pre-revenue or early-stage commercialization phase, typical for entities investing heavily in clinical trials to bring diagnostic tools to market. This valuation suggests the company is priced based on future potential and technological milestones rather than current cash generation or established sales volume.
Saúde financeira
The company reports a Net Income (TTM) of $-13,624,000 and an EBITDA of $-3,756,500, while the Revenue (TTM) figure is listed as N/A in the provided data. The substantial negative net income relative to the negative EBITDA reveals a significant gap caused by high operating expenses, likely driven by the capital-intensive nature of clinical stage research and development activities that do not yet generate sufficient revenue to cover costs. Free Cash Flow stands at $-1,058,125, indicating that the company is burning cash rather than generating liquidity, which limits its financial flexibility and necessitates reliance on external financing or existing cash reserves to fund operations. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that technically indicates that the reported financials are either pre-revenue or that revenue recognition methods result in zero margin calculation in the current reporting period. On the balance sheet side, the company holds $1.42M in cash against $139,000 in debt, resulting in a Debt to Equity ratio of 3.69, which suggests a leveraged position where equity is relatively small compared to total liabilities, though the low absolute debt amount mitigates immediate solvency risk. The Current Ratio is 0.71, which indicates that the company's current assets are insufficient to cover its current liabilities without relying on additional financing or the conversion of long-term assets. Furthermore, the Return on Equity is -130.1% and the Return on Assets is -20.8%, metrics that reveal that management has not yet achieved profitability and that the capital invested in the business is currently generating negative returns due to the ongoing losses associated with clinical development.
Avaliação de valorização
The Trailing P/E Ratio (TTM) and Forward P/E are both listed as N/A, which implies that the company is currently unprofitable and traditional price-to-earnings valuation multiples cannot be calculated or are not applicable for assessing the stock's value relative to earnings. The Price to Book ratio is 2.57, indicating that the market values the company's equity at 2.57 times its book value, a premium that often reflects the potential future value of intangible assets like intellectual property and clinical data that are not fully captured on the balance sheet. The Price to Sales ratio and EV/EBITDA are also N/A or negative (-2.23 for EV/EBITDA), suggesting that valuation must be approached with caution as the negative EV/EBITDA confirms the firm is not generating positive earnings before interest, taxes, depreciation, and amortization. Regarding price volatility, the 52-Week High is $3.92 and the 52-Week Low is $0.59, providing a trading range of $3.33 within which the stock has fluctuated over the last year. The Beta value is 0.79, which indicates that the stock price is generally less volatile than the broader market, moving with roughly 21% less intensity than the market average during periods of fluctuation. Investors researching the asset must note that the absence of a trailing P/E and the negative EV/EBITDA signal that the stock is being traded on speculative expectations rather than fundamental earnings performance.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning that no comparable historical data is available to calculate year-over-year growth rates, which is consistent with a company that may not have a long history of reported revenues or is in a stage where growth is measured in clinical milestones rather than financial percentages. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means that all available earnings or cash flow are theoretically retained within the business to fund ongoing research, development, and clinical trials rather than being distributed to shareholders. Since the Net Income is significantly negative, the payout ratio of 0.0% is sustainable only in the sense that the company is not obligated to pay dividends when it is currently incurring losses. The overall growth and income profile for Check-Cap Ltd. is characterized by a complete absence of current income generation and undefined historical growth rates, positioning the company as a pure-play speculative investment reliant entirely on the successful commercialization of its capsule-based screening technology products to transition from a cash-burning entity to a profitable revenue generator.